Navigation Links
Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
Date:8/9/2011

SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now reporting results to the International Scale. The test is being released as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert® System, detects the BCR-ABL mRNA transcript in the peripheral blood of patients with Chronic Myelogenous Leukemia (CML) in about two hours.

"Our work in the CML area is the first of several initiatives we are developing as we extend the GeneXpert System test menu into a new line of molecular diagnostic oncology products," said John Bishop, Cepheid's Chief Executive Officer. "The updated Xpert BCR-ABL Monitor test incorporates a fully validated test-specific conversion factor aligned to the International Scale — an important factor in helping to maintain consistency within and between laboratories to more accurately monitor patient progression toward remission."

CML is a cancer of the myeloid lineage of leukocytes (white blood cells) that is characterized by the presence of the "Philadelphia Chromosome," a reciprocal translocation of chromosomes 9 and 22 that results in the generation of the BCR-ABL fusion gene. The BCR-ABL protein functions as a constitutively activated Tyrosine Kinase that drives the proliferation of immature myeloid cells.

If untreated, CML progresses within several years from a chronic phase to accelerated and blastic phases, with survival in the blastic phase measured in months. The introduction of the targeted Tyrosine Kinase Inhibitors (TKIs) imatinib, dasatanib and nilotinib has had a profound impact on the survival of patients with CML. Since their introduction, CML has been transformed into a chronic condition with good long-term prognosis. Monitoring the levels of BCR-ABL mRNA transcript in the blood of CML patients on TKIs using real-time quantitative PCR has become standard of care in the management of CML. The goal of treatment is to reach a major molecular response (MMR), defined as a 3 log reduction (< 0.1%) in BCR-ABL mRNA levels from a standardized baseline defined by the International Scale(1,2). In order to accurately assess treatment response, it is essential that variability in testing methodologies be tightly controlled. This has resulted in substantial efforts to standardize BCR-ABL molecular testing across laboratories by introducing an International Scale(3).

The updated Xpert BCR-ABL Monitor is now available as a CE IVD Mark product. For more information, visit www.cepheidinternational.com for Cepheid's complete menu of CE IVD Xpert tests.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to planned new product releases, product performance and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing protocols; customer and market acceptance of our products; the failure of products to perform as fast or as accurately as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2010 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

References

  1. NCCN Guidelines™ version 2.2011 Chronic Myelogenous Leukemia
  2. Baccarani M et.al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041-51. Epub 2009 Nov
  3. Cayuela JM., Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica. 2011 May;96(5):664-71. Epub 2011 Feb 17

CONTACTS:For Media Inquiries:For Cepheid Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

408-400-8377

communications@cepheid.comJacquie Ross

Cepheid Investor Relations

408-400-8329

investor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast
3. Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner
4. Cepheid Appoints Vice President of Infectious Disease Research & Development
5. LABSCO to Distribute Cepheid GeneXpert® Systems and Tests
6. Cepheid Appoints LABSCO as US Small Hospital Distributor
7. Cepheid Reports 2011 First Quarter Results
8. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
9. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):